Drug intelligence / Profile preview

VAX-31

Development stage: Phase 3
Lead developer: Vaxcyte
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**VAX-31** is Vaxcyte's investigational 31-valent pneumococcal conjugate vaccine designed to prevent disease caused by *Streptococcus pneumoniae*, including invasive pneumococcal disease and pneumococcal pneumonia. It presents capsular polysaccharide antigens from 31 pneumococcal serotypes as conjugates using Vaxcyte's carrier-sparing platform, with the goal of eliciting serotype-specific functional antibodies and opsonophagocytic killing of pneumococci. VAX-31 is in a Phase 3 adult OPUS program and a Phase 2 infant program; it is not approved for use. ([vaxcyte.com](https://vaxcyte.com/pipeline/))

Brand names: Prevnar 20Prevnar20Prevnar-20
Other names: 31-valent pneumococcal conjugate vaccine

Targets

CPS (Streptococcus pneumoniae capsular polysaccharide)

Beyond the preview

Go deeper on VAX-31.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VAX-31.

Explore the full profile